图书馆订阅: Guest
Begell Digital Portal Begell 数字图书馆 电子图书 期刊 参考文献及会议录 研究收集
肿瘤形成评论综述™
SJR: 0.631 SNIP: 0.503 CiteScore™: 2.2

ISSN 打印: 0893-9675
ISSN 在线: 2162-6448

肿瘤形成评论综述™

DOI: 10.1615/CritRevOncog.2016016075
pages 141-154

Liquid Biopsies for Assessing Metastatic Melanoma Progression

Kelly Huynh
Department of Surgical Oncology, John Wayne Cancer Institute at Providence Saint John's Health Center, Santa Monica, CA 90404
Dave S.B. Hoon
Department of Molecular Oncology John Wayne Cancer Institute at Providence Saint John's Health Center Santa Monica, California

ABSTRACT

The field of genomic biomarkers in melanoma has evolved dramatically in the past few decades. Whereas much of the prior focus was on molecular assessment of tumor tissue, circulating tumor cells (CTCs), and cell-free circulating tumor DNA (ctDNA) as sources of a "liquid biopsy" in cancer patients provide promising potential as a method to assess tumor progression, identify targets for therapy, and evaluate clinical response to treatment. Blood biomarker assays have the advantage of being noninvasive, allow for dynamic evaluation of disease over a serial time frame, and help to address the issue of tissue sampling bias and tumor heterogeneity. However, there remains an assortment of technologies and techniques to isolate and detect CTCs and ctDNA and a standardized method has yet to be established. Despite these challenges, multiple studies have already demonstrated the clinical prognostic utility of blood-based genomic biomarker assays. With the advent of next-generation sequencing and genome-wide ctDNA analysis, this will undoubtedly lead to an improved understanding of tumor progression, help to identify new targets for treatment, and improve monitoring of treatment response and development of resistance.


Articles with similar content:

Pancreatic Cancer: An Emphasis on Current Perspectives in Immunotherapy
Critical Reviews™ in Oncogenesis, Vol.24, 2019, issue 2
Krishna Patel, Maya Nair, Riyaz Basha, Sohail Siraj, Jamboor K. Vishwanatha, Chloe Smith
Targeted Molecular Therapeutic Options for Hepatocellular Carcinoma
Critical Reviews™ in Oncogenesis, Vol.25, 2020, issue 1
Latha Neerukonda, Bassam Ghabach, Ishna Sharma, Kalyani Narra, Swathi Sridhar, Riyaz Basha, Umesh T. Sankpal
Liquid Biopsies in the Screening of Oncogenic Mutations in NSCLC and its Application in Targeted Therapy
Critical Reviews™ in Oncogenesis, Vol.20, 2015, issue 5-6
David Chia, Jason H. Tang
Circulating Tumor Cells in Breast Cancer Patients
Critical Reviews™ in Oncogenesis, Vol.21, 2016, issue 1-2
Lily Valad, Carolyn Hall, Anthony Lucci
From Molecular Tumor Diagnostics to Individualized Treatment with Phytochemicals Derived from Chinese Herbs
Forum on Immunopathological Diseases and Therapeutics, Vol.2, 2011, issue 4
Thomas Efferth